Compare Ascendis Pharma A/S (ASND) vs Cenovus Energy Inc (CVE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Cenovus Energy Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Cenovus Energy Inc trades at $26.76 (market cap $49.07B). The key difference: Cenovus Energy Inc is far larger — about 2.8× Ascendis Pharma A/S's market cap, and Cenovus Energy Inc pays a 2.35% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | CVE | |
|---|---|---|
Market Cap | $17.74B | $49.07B |
Sector | Health | Energy |
52-Week High | $277.18 | $31.80 |
52-Week Low | $163.32 | $13.96 |
Enterprise Value | $18.11B | $56.95B |
Dividend Yield | — | 2.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Cenovus Energy (CVE) trades at $26.40, up 1.62% today, with a bullish technical signal from moving averages. The stock shows strong fundamentals with a P/E of 14.93 and net income margin of 8.94%, supported by three consecutive quarterly earnings beats. Recent news highlights its 85% annual rally, driven by oil price gains and operational synergies from MEG Energy.
The outlook remains positive given its low-cost assets and integrated model, though risks include oil price volatility and execution of growth plans. Analyst consensus is mixed with 40.7% buy ratings, reflecting cautious optimism amid energy sector momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Cenovus Energy Inc
Cenovus Energy is an integrated oil company, focused on creating value through the development of its oil sands assets. The company also engages in production of conventional crude oil, natural gas liquids, and natural gas in Alberta, Canada, with refining operations in the U.S. Net upstream production averaged 472 thousand barrels of oil equivalent per day in 2020, and the company estimates that it holds 6.7 billion boe of proven and probable reserves.
Read more on CVE →
